The Formulation Innovation Network has been set up in the North of England as a means of enhancing innovation for all formulation-orientated businesses.
SurModics has opened a 90,000 sq ft cGMP manufacturing and development facility in Birmingham, Alabama, US to support its partnerships and shorten time to market.
Dr Reddy’s Laboratories is combining some of its products with Aegis Therapeutics’ Intravail drug delivery technology after the companies entered into a partnership.
Indian drugmaker Lupin can start seeking US approval for new drugs made at its API plant in Mandideep, Bhopal after resolving the cGMP deficiencies that earned the facility a US FDA warning last year.
AMRI’s plant in Rensselaer, New York gained SafeBridge potent compound certification this week after an effort that spokesperson Andrea Schulz said istestament to the firm's "willingness to go the extra mile”.
Access Pharmaceuticals’ insulin diabetes treatment has shown promise in preclinical trials, achieving over 80 per cent oral bioavailability, leading the company to target proof-of-concept studies in humans.
Lonza will shut down its API plant in Riverside, Pennsylvania, US by the end of the year as part of a plan to cut costs and shift small-molecule production to Asia.
Cel-Sci has completed validation of critical utilities and production equipment at its GMP facility which uses cold 4ºC aseptic filling to improve the shelf-life and potency and biologics.
Novavax has completed cGMP scale up of its RSV-F vaccine candidate, with the material being used in preclinical studies, and amended the terms of the H1N1 collaboration with Xcellerex.
A recently completed manufacturing and filling capacity expansion will help Florida Biologix meet deadlines and win repeat business according to company director Richard Snyder.
GSK says it will start making its BPH drug Avodart (dutasteride) at its facility in Poznan, Poland when it completes a PLN70m (€17m) capacity upgrade in January next year.
Vaccines could be produced in less than 10 weeks from first isolation of the RNA sequence by using insect cell derived influenza VLPs, according to research which has implications for H1N1 and H5N1.
Daiichi-Sankyo subsidiary Luitpold Pharmaceuticals has acquired PharmaForce, giving it a 40,000 sq ft cGMP compliant sterile manufacturing facility and a 20,000 sq ft API production plant.
InNexus Biotechnology believes 2010 is the year for biotechs to differentiate and has begun this process by using its Transmab delivery technology in a product for treating psoriasis.
Zydus Cadila has become the first Indian pharma company to begin multi-centre clinical trials of a H1N1 vaccine after it received approval from the Drug Controller General of India (DCGI).
Ownership of FrieslandCampina Domo’s pharmaceutical lactose business will be transferred to DMV-Fonterra Excipients, the 50/50 JV set up by Domo owner Royal FrieslandCampina and partner Fonterra.
Patheon says a slowdown in “outsourcing decision making,” manufacturing problems in Puerto Rico and cost related to JLL’s takeover bid hurt it in fiscal 09.
The Indian pharmaceutical market was worth $10.8bn (€7.5bn) this year and will more than double in value by 2014 according to a new industry report by Cygnus Business Consulting & Research.
Geron says the USPTO appeals board granted a request to declare “interference” between a patent application owned by the firm and one issued to Novocell in March.
US formulation services provider Bend Research says a new safety file for the bioavailability enhancing drug excipient, HPMCAS, can now be referenced by its clients in FDA filings.
Intercell’s needle-free patch delivery technology has the potential to change the way vaccines are delivered, according to Jean Stephenne, president of GSK Biologicals.
Unigene Laboratories is laying off one-third of its workforce and temporarily suspending production of some materials in an attempt to cut its operating expenses by up to $10m (€6.8m) in 2010.
Sanofi-Aventis will manufacture and supply recombinant human insulin crystals to Generex Biotechnology for use in Oral-lyn commercial production and clinical trials.
Hermes Biosciences has been acquired by Merrimack Pharmaceuticals in a deal which aims to combine the companies’ drug discovery and delivery platforms to develop cancer treatments.
CDMO Haupt Pharma has invested in a combined heat and power unit (CPHU) for its site in Wolfratshausen, Germany, which is now expected to produce 14 per cent less CO2 a year.
Roche has licensed Aegis Therapeutics’ ProTek stabilisation technology, which uses GRAS excipients to prevent aggregation and therefore improve production of peptide and protein drugs.
Indian API maker Avon Organics’ share price rocketed 10 per cent on the Bombay exchange yesterday after the US launch of a generic herpes treatment by Ranbaxy Laboratories.
Terapio has secured $5m (€3.3m) in funding to develop RLIP76, which is being used to counteract radiation and deliver large molecules across cell membranes, such as genetic material across the BBB.
Sinovac Biotech has formed a joint venture which will give it cost effective manufacturing capacity for 20m does of live attenuated vaccines and 20m doses of vero cell cultured vaccines a year.
Novartis says its new cell culture plant in Holly Springs, North Carolina could begin making its flu vaccine boosting MF59 adjuvant as early as next month if approved by US regulators.
A $150m (€100m) biologics manufacturing plant is being setup in Abu Dhabi to produce therapeutics for the Middle East and North Africa, according to the Khaleej Times.
Neurosurgeons have developed and used a novel intra-arterial (IA) technique to deliver Avastin (bevacizumab) directly into a malignant brain tumour, potentially administering a higher dose with reduced toxicity.
The FDA encourages innovation in excipients to develop new drugs or improve approved therapeutics and IPEC is helping to drive acceptance of these novel products, according to BASF.
Spanish ingredient supplier Cafosa has launched a new directly compressible pharmaceutical excipient for medicated chewing gums that, it claims, can boost patient compliance.
French drug delivery specialist Galenix has named DSM’s pharmaceutical products unit as its manufacturing and co-marketing partner as it continues to efforts build its global presence.
